Department of Thoracic Surgery, Affiliated Provincial Hospital of Anhui Medical University, Hefei, China.
School of Nursing, Anhui University of Traditional Chinese Medicine, Hefei, China.
Thorac Cancer. 2020 May;11(5):1309-1318. doi: 10.1111/1759-7714.13398. Epub 2020 Mar 19.
This study aimed to investigate the effect of type 2 diabetes mellitus on survival of patients with non-small cell lung cancer (NSCLC).
We retrospectively analyzed NSCLC patients who had undergone radical lung cancer surgery from January 2011 to December 2014 in the Anhui Medical University affiliated Anhui Provincial Hospital. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards regression models were used to describe the effect of type 2 diabetes mellitus on the overall survival of patients with NSCLC.
A total of 769 patients with NSCLC were enrolled, including 126 in the diabetic mellitus group and 643 in the nondiabetic mellitus group. The one, three, and five-year survival for patients with and without diabetes mellitus were 86.1% versus 89.6%, 49.5% versus 62.4%, and 33.3% versus 40.6%, respectively. The Cox model showed that type 2 diabetes mellitus was a poor independent prognostic factors for NSCLC patients. In addition, metformin is a good independent prognostic factor for patients with non-small cell lung cancer with type 2 diabetes mellitus.
NSCLC patients without type 2 diabetes mellitus have an increased survival rate compared with those with type 2 diabetes mellitus.
本研究旨在探讨 2 型糖尿病对非小细胞肺癌（NSCLC）患者生存的影响。
我们回顾性分析了 2011 年 1 月至 2014 年 12 月在安徽医科大学附属安徽省立医院接受根治性肺癌手术的 NSCLC 患者。采用 Kaplan-Meier 图、log-rank 检验和 Cox 比例风险回归模型描述 2 型糖尿病对 NSCLC 患者总生存的影响。
共纳入 769 例 NSCLC 患者，其中糖尿病组 126 例，非糖尿病组 643 例。有糖尿病和无糖尿病患者的 1、3、5 年生存率分别为 86.1%与 89.6%、49.5%与 62.4%、33.3%与 40.6%。Cox 模型显示，2 型糖尿病是 NSCLC 患者的不良独立预后因素。此外，二甲双胍是 2 型糖尿病合并非小细胞肺癌患者的良好独立预后因素。
与 2 型糖尿病患者相比，无 2 型糖尿病的 NSCLC 患者生存率更高。
